- Home
- BBW vs CVAC Comparison
BBW vs CVAC Comparison
Compare BBW & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBW
- CVAC
- Stock Information
- Founded
- BBW 1997
- CVAC 2000
- Country
- BBW United States
- CVAC Germany
- Employees
- BBW N/A
- CVAC N/A
- Industry
- BBW Recreational Games/Products/Toys
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BBW Consumer Discretionary
- CVAC Health Care
- Exchange
- BBW Nasdaq
- CVAC Nasdaq
- Market Cap
- BBW 554.5M
- CVAC 637.1M
- IPO Year
- BBW 2004
- CVAC 2020
- Fundamental
- Price
- BBW $43.43
- CVAC $2.95
- Analyst Decision
- BBW Strong Buy
- CVAC Hold
- Analyst Count
- BBW 3
- CVAC 3
- Target Price
- BBW $54.33
- CVAC $10.00
- AVG Volume (30 Days)
- BBW 337.9K
- CVAC 523.1K
- Earning Date
- BBW 12-05-2024
- CVAC 11-12-2024
- Dividend Yield
- BBW 1.84%
- CVAC N/A
- EPS Growth
- BBW 8.16
- CVAC N/A
- EPS
- BBW 3.79
- CVAC N/A
- Revenue
- BBW $495,235,000.00
- CVAC $70,565,734.00
- Revenue This Year
- BBW $2.56
- CVAC $738.59
- Revenue Next Year
- BBW $2.52
- CVAC N/A
- P/E Ratio
- BBW $11.48
- CVAC N/A
- Revenue Growth
- BBW 2.76
- CVAC 75.11
- 52 Week Low
- BBW $21.24
- CVAC $2.22
- 52 Week High
- BBW $47.01
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- BBW 61.16
- CVAC 49.55
- Support Level
- BBW $40.93
- CVAC $3.17
- Resistance Level
- BBW $43.09
- CVAC $3.56
- Average True Range (ATR)
- BBW 2.35
- CVAC 0.18
- MACD
- BBW 0.27
- CVAC 0.01
- Stochastic Oscillator
- BBW 63.02
- CVAC 24.69
About BBW Build-A-Bear Workshop Inc.
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.